Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $44.60 USD
Change Today +0.62 / 1.41%
Volume 729.3K
NUVA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NUVA) Snapshot

Open
$43.89
Previous Close
$43.98
Day High
$45.01
Day Low
$43.62
52 Week High
01/8/15 - $51.23
52 Week Low
04/30/14 - $31.35
Market Cap
2.1B
Average Volume 10 Days
550.7K
EPS TTM
$0.42
Shares Outstanding
48.1M
EX-Date
--
P/E TM
107.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVASIVE INC (NUVA)

nuvasive inc (NUVA) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NUVA) Details

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product is Maximum Access Surgery (MAS), a minimally-disruptive surgical platform that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing process consist of Osteocel Plus and Osteocel Pro allograft (donated human tissue), which are cellular matrix products containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during non-spine. The company sells its products through independent sales agencies, directly-employed sales shareowners to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,500 Employees
Last Reported Date: 02/25/15
Founded in 1997

nuvasive inc (NUVA) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.0K
President and Chief Operating Officer
Total Annual Compensation: $520.0K
President of US Sales and Services
Total Annual Compensation: $375.0K
Special Advisor To The Chief Executive Office...
Total Annual Compensation: $550.0K
Compensation as of Fiscal Year 2013.

nuvasive inc (NUVA) Key Developments

NuVasive Seeks Acquisitions

NuVasive, Inc. (NasdaqGS:NUVA) is looking for acquisitions. Quentin Blackford, Exexcutive Vise President and Chief financial Officer of NuVasive states, "At the same time we want to balance that with our appetite to be acquisitive. We want to play in the M&A space. There are opportunities to grow our international business and expand the scale of that business rapidly in some key markets. We want to look at those opportunities and ensure that we have the potential to do it."

NuVasive Announces Successful Appeal of Medtronic Verdict

NuVasive, Inc. announced that the Court of Appeals for the Federal Circuit overturned the damages award in the Company's ongoing patent lawsuit with Medtronic Sofamor Danek USA, Inc. and Warsaw Orthopedic, Inc. The appeal challenged a September 2011 jury verdict in the first phase of the litigation between NuVasive and Medtronic. The jury found that the three remaining patents at issue in the appeal were infringed awarding total monetary damages of $660,000 to NuVasive and approximately $102 million to Medtronic, which included lost profits, the sale of ancillary or 'convoyed' products and royalties. On March 2, 2015, the three Judge panel of the Court of Appeals issued a unanimous decision upholding the jury's finding of liability as to all patents, but overturning the damage award against NuVasive as improper. Significantly, the Court of Appeals held that the damages award was erroneous because Medtronic is not permitted to recover damages for lost profits or for the sale of convoyed products. Absent further proceedings on appeal, the case will be returned to the District Court for further proceedings to determine a proper damage award based solely on a reasonable royalty. The timing of a retrial to determine the new damages amount is difficult to predict, but could occur later in 2015.

NuVasive, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

NuVasive, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of $204,324,000 against $190,815,000 a year ago. Income before income taxes was $17,643,000 against $8,600,000 a year ago. Net income was $7,292,000 against $5,837,000 a year ago. Net income attributable to the company was $7,473,000 or $0.16 diluted per share against $6,009,000 or $0.13 diluted per share a year ago. On a non-GAAP basis, the Company reported net income of $20.0 million, or $0.39 per share, for the fourth quarter 2014 compared to net income of $17.8 million, or $0.37 per share, for the fourth quarter 2013. For the year, the company reported revenue of $762,415,000 against $685,173,000 a year ago. Loss before income taxes was $11,210,000 against income of $9,768,000 a year ago. Net loss was $17,496,000 against net income of $6,985,000 a year ago. Net loss attributable to the company was $16,720,000 or $0.36 diluted per share against net income of $7,902,000 or $0.18 diluted per share a year ago. Net cash provided by operating activities was $115,548,000 against $97,439,000 a year ago. Purchases of property and equipment were $58,424,000 against $47,597,000 a year ago. Non-GAAP earnings were $57,358,000 or $1.23 per share. On a non-GAAP basis, the company reported net income of $57.5 million, or $1.16 per share, for the full year 2014 compared to net income of $57.4 million, or $1.23 per share, for the full year 2013. For 2014, the company expects revenue of approximately $810.0 million, which includes an approximate $10.0 million of currency headwinds, or 6.0% growth compared to 2014 revenue of $762.4 million; on a constant currency basis revenue is expected to grow 7.5%; GAAP earnings per share of approximately $0.67 compared to 2014 GAAP loss per share of $0.36; Non-GAAP earnings per share of approximately $1.10, an increase of approximately 64.0% compared to non-GAAP earnings of $0.67 for 2014; Non-GAAP operating margin of approximately 14.4%, an increase of approximately 300 basis points compared to 11.4% for 2014; this is an increase of 50 basis points from previous expectations of an approximate 250 basis point improvement expected in 2015; Non-GAAP EBITDA margin of approximately 24.6%, an increase of approximately 270 basis points compared to 21.9% for 2014; GAAP effective tax expense rate of approximately 49%; and Non-GAAP effective tax expense rate of approximately 46%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NUVA:US $44.60 USD +0.62

NUVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $50.36 USD +0.96
Globus Medical Inc $24.58 USD +0.51
Integra LifeSciences Holdings Corp $60.50 USD -0.02
Masimo Corp $31.84 USD +0.42
Thoratec Corp $41.00 USD +0.96
View Industry Companies
 

Industry Analysis

NUVA

Industry Average

Valuation NUVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit www.nuvasive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.